1)Zheng XL, Wu HM, Shang D, et al:Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica 95:1555-1562,2010
2)Graça NAG, Joly BS, Voorberg J, et al:TTP: From empiricism for an enigmatic disease to targeted molecular therapies. Br J Haematol 197:156-170,2022
3)Kangro K, Roose E, Joly BS, et al:Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura. Blood Adv 5:3427-3435,2021
4)Sakai K, Matsumoto M, De Waele L, et al:ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura. Blood Adv 7:131-140,2023
5)South K, Luken BM, Crawley JT, et al:Conformational activation of ADAMTS13. Proc Natl Acad Sci U S A 111:18578-18583,2014
6)Roose E, Schelpe AS, Joly BS, et al:An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 16:378-388,2018
7)Roose E, Schelpe AS, Tellier E, et al:Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood 136:353-361,2020
8)Chemnitz J, Draube A, Scheid C, et al:Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 71:105-108,2002
9)Gutterman LA, Kloster B, Tsai HM:Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 28:385-391,2002
10)Scully M, Cohen H, Cavenagh J, et al:Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 136:451-461,2007
11)Froissart A, Buffet M, Veyradier A, et al:Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 40:104-111,2012
12)Miyakawa Y, Imada K, Ichinohe T, et al:Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy. Int J Hematol 104:228-235,2016
13)厚生労働科学研究費補助金 難治性疾患政策研究事業 「血液凝固異常症等に関する研究班」TTPグループ,松本雅則,宮川義隆,他:血栓性血小板減少性紫斑病診療ガイド2023.臨血 64:445-460,2023
14)Scully M, McDonald V, Cavenagh J, et al:A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 118:1746-1753,2011
15)Westwood JP, Webster H, McGuckin S, et al:Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 11:481-490,2013
16)Zheng XL, Vesely SK, Cataland SR, et al:ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost 18:2496-2502,2020
17)Coppo P, Bubenheim M, Azoulay E, et al:A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood 137:733-742,2021
18)Dutt T, Shaw RJ, Stubbs M, et al:Real-world experience with caplacizumab in the management of acute TTP. Blood 137:1731-1740,2021
19)Scully M, Rayment R, Clark A, et al:A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. Br J Haematol, 2023, in press
20)Peyvandi F, Lavoretano S, Palla R, et al:ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 93:232-239,2008
21)Zheng XL, Vesely SK, Cataland SR, et al:Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost 18:2503-2512,2020
22)Hie M, Gay J, Galicier L, et al:Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 124:204-210,2014
23)Jestin M, Benhamou Y, Schelpe AS, et al:Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood 132:2143-2153,2018
24)Westwood JP, Thomas M, Alwan F, et al:Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Blood Adv 1:1159-1166,2017
25)Shin JS, Subhan MO, Cambridge G, et al:Alterations in B- and circulating T-follicular helper cell subsets in immune thrombotic thrombocytopenic purpura. Blood Adv 6:3792-3802,2022
26)Chen M, Shortt J:Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP). Transfus Med Rev 36:204-214,2022
27)Ulrichts H, Silence K, Schoolmeester A, et al:Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 118:757-765,2011
28)Peyvandi F, Scully M, Kremer Hovinga JA, et al:Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 374:511-522,2016
29)Scully M, Cataland SR, Peyvandi F, et al:Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 380:335-346,2019
30)Miyakawa Y, Imada K, Ichikawa S, et al:The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study. Int J Hematol 117:366-377,2023
31)Chander DP, Loch MM, Cataland SR, et al:Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 381:92-94,2019
32)Kühne L, Knoebl P, Eller K, et al:Plasma exchange-free management of immune thrombotic thrombocytopenic purpura: the Austrian-German experience, ISTH Academy, 2023(https://academy.isth.org/isth/2023/isth-2023-congress/392242/lucas.khne.plasma.exchange-free.management.of.immune.thrombotic.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dcaplacizumab)(最終アクセス:2023年10月1日)
33)Goshua G, Sinha P, Hendrickson JE, et al:Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 137:969-976,2021
34)Völker LA, Kaufeld J, Miesbach W, et al:ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP. Blood Adv 4:3093-3101,2020
35)Kühne L, Kaufeld J, Völker LA, et al:Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura. J Thromb Haemost 20:951-960,2022
36)Chaturvedi S, Yu J, Brown J, et al:Silent cerebral infarction during immune TTP remission: prevalence, predictors, and impact on cognition. Blood 142:325-335,2023